Please find enclosed herewith the Notice of the 52nd Annual General Meeting of the Company scheduled to be held on Thursday, 27th August, 2026 at 11.00 a.m. through Video Conferencing (VC)/ ....

29th July, 2026 The Corporate Relationship Department National Stock Exchange of India Limited BSE Limited Exchange Plaza, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Dalal Street, Bandra East, Mumbai 400 001. Mumbai 400 051. Scrip Code: 539523 Scrip Symbol: ALKEM Sub: Notice of the 52nd Annual General Meeting (AGM) and Annual Report for financial year 2025-2026. Dear Sir/Madam, Please find enclosed herewith the Notice of the 52nd Annual General Meeting of the Company scheduled to be held on Thursday, 27th August, 2026 at 11.00 a.m. through Video Conferencing (VC)/ Other Audio-Visual Means (OAVM) alongwith the Annual Report for financial year 2025-2026. The same is also available on the website of the Company at www.alkemlabs.com Kindly take the same on record. Thanking you Sincerely, For Alkem Laboratories Limited Divya Mewani Vice President – Legal and Deputy Company Secretary Encl: a/a The Next Shape of Growth Alkem Laboratories Limited Annual Report 2025-26 What’s Inside The Next Shape of Growth 1 Manufacturing Excellence 40 - 41 Innovation and R&D 42 - 45 Corporate Overview 2 - 77 Human Capital 46 - 49 Company Overview 2 - 5 Environment, Health, Safety & Year in Numbers 6 - 7 Sustainability (EHSS) 50 - 55 Reach and Presence 8 - 9 CSR Roadmap & Strategic Direction 56 - 63 Journey So Far 10 - 11 Governance 64 - 73 Financial Performance 12 - 13 The Way Ahead 74 - 75 Value Creation Model 14 - 15 Awards & Recognitions 76 Capital Allocation Story 16 - 17 Corporate Information 77 Chairman's Letter 18 - 19 Statutory Reports 78 - 190 MD’s Communique 20 - 21 Management, Discussion & CEO's Message 22 - 23 Analysis Report 78 - 101 Core Momentum 24 - 25 Directors' Report 102 - 127 Global Growth Mix 26 - 27 Corporate Governance Report 128 - 150 Business Responsibility & Capability-led Expansion 28 - 29 Sustainability Report (BRSR) 151 - 190 Seeds of the Next Curve 30 - 31 Financial Statements 191-358 Growth Architecture 32 - 33 Standalone Financial Statements 191 - 272 Strategic Enablers 34 - 35 Consolidated Financial Statements 273 - 358 Risk Management 36 - 39 Notice of AGM 359 - 371 Concept Note The Next Shape of Growth reflects Alkem Laboratories Limited's evolution into a future- ready healthcare organisation, building on a strong foundation while expanding into new opportunities. The tree, rooted in a DNA helix, symbolises innovation as the source of enduring growth, with deep roots representing scientific excellence, trust and resilience. The icons across the canopy represent the Company's diversified portfolio spanning Domestic Pharma, Branded and Trade Generics, OTx and APIs, ActivLife and Alkem Activa, International Business, Biotech including Biosimilars and Bio CDMO, and MedTech. The infinity symbol signifies limitless possibilities, highlighting Alkem's commitment to sustained value creation, broader healthcare impact and long-term growth. What’s Inside The Next Shape of Growth The Next Shape of Growth 1 Manufacturing Excellence 40 - 41 Innovation and R&D 42 - 45 For over five decades, Alkem’s growth journey has Corporate Overview 2 - 77 Human Capital 46 - 49 been shaped by a strong and consistent foundation Company Overview 2 - 5 Environment, Health, Safety & — building trusted brands, expanding access to Year in Numbers 6 - 7 Sustainability (EHSS) 50 - 55 medicines, deepening therapy presence, driving Reach and Presence 8 - 9 CSR Roadmap & Strategic Direction 56 - 63 innovation, and creating operational excellence. Journey So Far 10 - 11 Governance 64 - 73 Financial Performance 12 - 13 The Way Ahead 74 - 75 This foundation has enabled Alkem to build a resilient pharmaceutical business with a strong India franchise and a growing global presence. The next phase of growth builds on Value Creation Model 14 - 15 Awards & Recognitions 76 this strength, while expanding the boundaries of what the company can achieve. Capital Allocation Story 16 - 17 Corporate Information 77 “The Next Shape of Growth” represents the evolution of Alkem from a successful Chairman's Letter 18 - 19 Statutory Reports 78 - 190 pharmaceutical company into a broader healthcare enterprise — one that continues to MD’s Communique 20 - 21 Management, Discussion & strengthen its core while building new engines of future growth. CEO's Message 22 - 23 Analysis Report 78 - 101 The theme reflects a transition from growth driven primarily by scale and market Core Momentum 24 - 25 Directors' Report 102 - 127 expansion to growth powered by capability building, innovation and diversification. The Global Growth Mix 26 - 27 Corporate Governance Report 128 - 150 established business remains the foundation — generating resilience, cash flows and Business Responsibility & competitive strength — while emerging platforms create opportunities for the future. Capability-led Expansion 28 - 29 Sustainability Report (BRSR) 151 - 190 Seeds of the Next Curve 30 - 31 Three strategic areas represent this next chapter: Financial Statements 191-358 Growth Architecture 32 - 33 Building beyond the traditional pharmaceutical model Standalone Financial Statements 191 - 272 Strategic Enablers 34 - 35 Alkem is expanding its presence into high-growth healthcare segments, including Consolidated Financial Statements 273 - 358 MedTech, where the focus is on creating differentiated capabilities and participating in Risk Management 36 - 39 emerging opportunities. Notice of AGM 359 - 371 Strengthening innovation-led growth The advancement of biosimilars and newer therapeutic platforms reflects Alkem’s commitment to building future-ready capabilities and addressing evolving healthcare needs. Preparing for the next wave of healthcare opportunities The entry into areas such as GLP-1 therapies demonstrates the company’s ability to anticipate market evolution and position itself early in high-potential segments. These initiatives are not separate growth avenues; they are interconnected parts of a larger strategy. The strength of the core business enables investments in future opportunities, and these emerging businesses, over time, are expected to become contributors to the next phase of sustainable growth. Concept Note The Next Shape of Growth is not about changing who Alkem is — it is about expanding what Alkem can become. The Next Shape of Growth reflects Alkem Laboratories Limited's evolution into a future- ready healthcare organisation, building on a strong foundation while expanding into new It represents a more diversified, innovation-driven and future-ready healthcare opportunities. The tree, rooted in a DNA helix, symbolises innovation as the source of enterprise, built on the same values and strengths that have defined the company for enduring growth, with deep roots representing scientific excellence, trust and resilience. more than fifty years. The icons across the canopy represent the Company's diversified portfolio spanning Domestic Pharma, Branded and Trade Generics, OTx and APIs, ActivLife and Alkem Activa, International Business, Biotech including Biosimilars and Bio CDMO, and MedTech. The infinity symbol signifies limitless possibilities, highlighting Alkem's commitment to sustained value creation, broader healthcare impact and long-term growth. Alkem Laboratories Limited The Next Shape of Growth Company Overview Built to Scale, Engineered to Endure A diversified healthcare company headquartered in Mumbai, with a domestic prescription business that ranks among India’s largest, an international platform now spanning more than forty countries, and a growing presence in MedTech, biosimilars, Active Pharmaceutical Ingredients, and consumer wellness. What we do Multiple healthcare platforms with One Philosophy: A shared commitment to improving lives through accessible, high-quality healthcare solutions. Domestic Pharma | Branded & Trade Generics OTx & APIs | ActivLife and Alkem Activa Our core franchise is built on a strong foundation of Our consumer health franchise, ActivLife, led by the trusted pres [Showing first 8,000 characters — download PDF for full document]